Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2011: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
|
Outline of Final Research Achievements |
Amyloid beta peptide (A beta) is a potential biomarker to evaluate the risk of Alzheimer's disease. Our purpose in this study was to develop a preclinical diagnostic device for Alzheimer's disease with ultra high sensitivity, ease, and high-through put, and at low cost. Using an A beta aggregation promoting peptide which was developed by us, we can detect ~10 nM of A beta quantitatively within 1 hour. We are now trying to improve the sensitivity to detect plasma A beta and put it to practical use.
|